Urinary tract obstruction
disease diseaseOn this page
Also known as obstructive uropathyurinary obstruction
Summary
Urinary tract obstruction (MONDO:0003330) is a disease with 1 GWAS associations across 9 studies and 16 clinical trials. Top therapeutic interventions include finasteride and tamsulosin. A subtype of urinary system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 16
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | urinary tract obstruction |
| Mondo ID | MONDO:0003330 |
| EFO | EFO:0009571 |
| DOID | DOID:5200 |
| NCIT | C3675 |
| SNOMED CT | 7163005 |
| UMLS | C0178879 |
| MedGen | 64247 |
| Is cancer (heuristic) | no |
Also known as: obstructive uropathy · urinary obstruction
Data availability: 1 GWAS association (9 studies).
Disease family
This is a subtype of urinary system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary tract obstruction
Related subtypes (19): bacteriuria, ureteral disorder, pyuria, urethral disorder, kidney disorder, urinary bladder disorder, hyperglycinuria, hypercalciuria, absorptive, 2, hypercalciuria, absorptive, 1, megacystis-megaureter syndrome, postorgasmic illness syndrome, congenital urachal anomaly, urinary system neoplasm, urothelial hyperplasia, urolithiasis, urinary tract infection, meningitis-retention syndrome, paraneoplastic renal syndrome, idiopathic hypercalciuria
Subtypes (2): ureteral obstruction, hydronephrosis
Genetics & variants
GWAS landscape
1 GWAS associations across 9 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs191961172 | 3e-12 | RIOX2 | A | 2.21 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90080578 | Backman JD | 2021 | 3,650 | 383,346 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90084564 | Backman JD | 2021 | 3,650 | 383,346 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90478593 | Verma A | 2024 | 2,798 | 442,088 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90478592 | Verma A | 2024 | 743 | 119,678 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480401 | Verma A | 2024 | 743 | 119,678 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90727120 | Kim HI | 2026 | 583 | 43,443 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90482231 | Verma A | 2024 | 374 | 58,795 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90246179 | Walters RG | 2023 | 204 | 75,695 | Genotyping and population characteristics of the China Kadoorie Biobank. |
| GCST90436452 | Zhou W | 2018 | 164 | 384,930 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 1 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs191961172 | 3 | 97950502 | A>C | 0 | intron_variant | RIOX2 | 3e-12 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 16.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05359484 | PHASE2/PHASE3 | COMPLETED | Delta Q Value to Discriminate Detrusor Underactivity From Bladder Outlet Obstruction |
| NCT05640115 | EARLY_PHASE1 | WITHDRAWN | Obstruction of Malignancy: Percutaneous Renal vs Endoscopic Stent |
| NCT04288427 | Not specified | RECRUITING | 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy |
| NCT06336304 | Not specified | RECRUITING | NXT Post-Market Clinical Follow-up |
| NCT02055430 | Not specified | COMPLETED | Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage |
| NCT02138877 | Not specified | COMPLETED | Dismembered Pyeloplasty With and Without After Coming Stent |
| NCT02139059 | Not specified | UNKNOWN | Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria |
| NCT03936673 | Not specified | COMPLETED | Effect of Nephrostomy on Relative Function of Obstructed Kidney |
| NCT04332861 | Not specified | COMPLETED | Evaluation of Infection in Obstructing Urolithiasis |
| NCT04594161 | Not specified | COMPLETED | Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis |
| NCT04599283 | Not specified | COMPLETED | BE Technologies Mobile Uroflowmetry Validation Study |
| NCT04605835 | Not specified | UNKNOWN | Ultrasonic Visualization of Obstructive Uropathies in Children |
| NCT04870749 | Not specified | COMPLETED | The Importance of Non-invasive Methods in the Diagnosis of Lower Urinary System Symptoms. |
| NCT06040736 | Not specified | COMPLETED | Point-of-care Ultrasound to Assess Hydronephrosis in Patients With Acute Kidney Injury in the Emergency Department |
| NCT06181175 | Not specified | UNKNOWN | Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial |
| NCT06260917 | Not specified | COMPLETED | The Effect of Urinating Through the Zipper or by Pulling Down the Trousers on Uroflowmetry Parameters in LUTS |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FINASTERIDE | 4 | 1 |
| TAMSULOSIN | 4 | 1 |
| CHEMBL4777013 | 0 | 1 |
Related Atlas pages
- Drugs: Finasteride, Tamsulosin